NEW YORK (360Dx) – OncoDNA said this week that new guidelines from the Spanish Society of Pathology and the Spanish Society of Medical Oncology now endorse genomic testing to identify cancers of unknown primary origin using tools like OncoDNA's OncoDEEP product — a combined DNA and protein assay performed on solid tumor samples.
The company presented data at the annual congress of the Spanish Society of Medical Oncology last month showing that OncoDEEP could be used to identify the origins of a tumor in more than 80 percent of cases and could detect potentially actionable mutations in more than 60 percent of cases.
Interpace Diagnostics reported this week that it has entered into an agreement with Piedmont Healthcare, Georgia's largest healthcare system, enabling all physicians in the Piedmont Healthcare Network to use the company's PancraGen molecular pancreatic cancer risk classifier for patients with indeterminate pancreatic cysts or other pancreaticobiliary lesions. Interpace recently announced an expansion of the applications for PancraGen to include biliary strictures and solid lesions.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.